A. Pinto, P. Dickman, and D. Parham, Pathobiologic Markers of the Ewing Sarcoma Family of Tumors: State of the Art and Prediction of Behaviour, Sarcoma, vol.280, issue.2, p.856190, 2011.
DOI : 10.1016/j.cancergencyto.2007.11.002

G. Stoll, D. Surdez, and F. Tirode, Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis, Nucleic Acids Research, vol.9, issue.19, pp.8853-71, 2013.
DOI : 10.1074/mcp.M110.000406

R. Womer, D. West, and M. Krailo, Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group, Journal of Clinical Oncology, vol.30, issue.33, pp.4148-54, 2012.
DOI : 10.1200/JCO.2011.41.5703

N. Oz?-oren and W. El-deiry, Defining Characteristics of Types I and II Apoptotic Cells in Response to TRAIL, Neoplasia, vol.4, issue.6, pp.551-558, 2002.
DOI : 10.1038/sj.neo.7900270

H. Kontny, K. Klein, and R. , Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis, Cell Death & Differentiation, vol.139, issue.5, pp.506-520, 2001.
DOI : 10.1016/0022-1759(91)90198-O

N. Mitsiades, V. Poulaki, and C. Mitsiades, Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5, Cancer Res, vol.61, pp.2704-2716, 2001.

F. Van-valen, S. Fulda, and B. Truckenbrod, Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), International Journal of Cancer, vol.3, issue.2, pp.252-261, 2000.
DOI : 10.1016/1074-7613(95)90057-8

M. Merchant, X. Yang, and F. Melchionda, Interferon ?? Enhances the Effectiveness of Tumor Necrosis Factor-Related Apoptosis???Inducing Ligand Receptor Agonists in a Xenograft Model of Ewing???s Sarcoma, Cancer Research, vol.64, issue.22, pp.8349-56, 2004.
DOI : 10.1158/0008-5472.CAN-04-1705

G. Picarda, F. Lamoureux, and L. Geffroy, Preclinical Evidence that Use of TRAIL in Ewing's Sarcoma and Osteosarcoma Therapy Inhibits Tumor Growth, Prevents Osteolysis, and Increases Animal Survival, Clinical Cancer Research, vol.16, issue.8, pp.2363-74, 2010.
DOI : 10.1158/1078-0432.CCR-09-1779

S. Kelley, L. Harris, and D. Xie, Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety, J Pharmacol Exp Ther, vol.299, pp.31-39, 2001.

A. Ashkenazi, P. Holland, and S. Eckhardt, Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor???Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL), Journal of Clinical Oncology, vol.26, issue.21, pp.3621-3651, 2008.
DOI : 10.1200/JCO.2007.15.7198

L. Sasportas, R. Kasmieh, and H. Wakimoto, Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy, Proceedings of the National Academy of Sciences, vol.9, issue.5, pp.4822-4829, 2009.
DOI : 10.1593/neo.07223

H. Barti-juhasz, R. Mihalik, and K. Nagy, Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro, Haematologica, vol.96, issue.3, pp.21-22, 2011.
DOI : 10.3324/haematol.2010.036822

C. Carlo-stella, C. Lavazza, and M. Nicola, Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand, Human Gene Therapy, vol.17, issue.12, pp.1225-1265, 2006.
DOI : 10.1089/hum.2006.17.1225

M. Loebinger, A. Eddaoudi, and D. Davies, Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer, Cancer Research, vol.69, issue.10, pp.4134-4176, 2009.
DOI : 10.1158/0008-5472.CAN-08-4698

A. Mohr, M. Lyons, and L. Deedigan, Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model, Journal of Cellular and Molecular Medicine, vol.18, issue.6b, pp.2628-2671, 2008.
DOI : 10.1089/hum.2007.034

Z. Yuan, K. Kolluri, E. Sage, K. Gowers, and S. Janes, Mesenchymal stromal cell delivery of full-length tumor necrosis factor???related apoptosis-inducing ligand is superior to soluble type for cancer therapy, Cytotherapy, vol.17, issue.7, pp.885-96, 2015.
DOI : 10.1016/j.jcyt.2015.03.603

G. Grisendi, R. Bussolari, and L. Cafarelli, Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy, Cancer Research, vol.70, issue.9, pp.3718-3747, 2010.
DOI : 10.1158/0008-5472.CAN-09-1865

S. Ciavarella, G. Grisendi, and M. Dominici, In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells, British Journal of Haematology, vol.7, issue.5, pp.586-98, 2012.
DOI : 10.1089/107632701300062859

G. Grisendi, C. Spano, D. Souza, and N. , Mesenchymal Progenitors Expressing TRAIL Induce Apoptosis in Sarcomas, STEM CELLS, vol.94, issue.3, pp.859-69, 2015.
DOI : 10.1038/sj.bjc.6603092
URL : http://onlinelibrary.wiley.com/doi/10.1002/stem.1903/pdf

G. Picarda, V. Trichet, and S. , TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment
URL : https://hal.archives-ouvertes.fr/inserm-00667881

R. Guiho, K. Biteau, and D. Heymann, TRAIL-based therapy in pediatric bone tumors: how to overcome resistance, Future Oncology, vol.2, issue.1, pp.535-577, 2015.
DOI : 10.1186/1471-2407-14-74

D. Miguel, D. Gallego-lleyda, A. Anel, and A. , Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells, Leukemia Research, vol.39, issue.6, pp.657-66, 2015.
DOI : 10.1016/j.leukres.2015.03.019

K. Azijli, B. Weyhenmeyer, and G. Peters, Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family, Cell Death & Differentiation, vol.169, issue.7, pp.858-68, 2013.
DOI : 10.1016/j.ccr.2008.02.003

A. Karnoub, A. Dash, and A. Vo, Mesenchymal stem cells within tumour stroma promote breast cancer metastasis, Nature, vol.9, issue.7162, pp.557-63, 2007.
DOI : 10.3233/BD-2007-26107

W. Zhu, W. Xu, and R. Jiang, Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo, Experimental and Molecular Pathology, vol.80, issue.3, pp.267-74, 2006.
DOI : 10.1016/j.yexmp.2005.07.004

G. Bonuccelli, S. Avnet, and G. Grisendi, Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells, Oncotarget, vol.5, issue.17, pp.7575-88, 2014.
DOI : 10.18632/oncotarget.2243

P. Perrot, J. Rousseau, and A. Bouffaut, Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence, PLoS ONE, vol.17, issue.6, p.10999, 2010.
DOI : 10.1371/journal.pone.0010999.s001
URL : https://hal.archives-ouvertes.fr/inserm-00667931

P. Avril, L. Nail, L. Brennan, and M. A. , Mesenchymal stem cells increase proliferation but do not change quiescent state of osteosarcoma cells: Potential implications according to the tumor resection status, Journal of Bone Oncology, vol.5, issue.1, pp.5-14, 2016.
DOI : 10.1016/j.jbo.2015.11.002

L. Qiao, Z. Xu, and T. Zhao, Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling, Cancer Letters, vol.269, issue.1, pp.67-77, 2008.
DOI : 10.1016/j.canlet.2008.04.032

L. Qiao, Z. Xu, and T. Zhao, Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model, Cell Research, vol.18, issue.4, pp.500-507, 2008.
DOI : 10.1007/s00418-003-0561-0

Y. Zhu, Z. Sun, and Q. Han, Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1, Leukemia, vol.449, issue.5, pp.925-958, 2009.
DOI : 10.1038/leu.2008.384
URL : http://www.nature.com/leu/journal/v23/n5/pdf/leu2008384a.pdf

P. Secchiero, S. Zorzet, and C. Tripodo, Human Bone Marrow Mesenchymal Stem Cells Display Anti-Cancer Activity in SCID Mice Bearing Disseminated Non-Hodgkin's Lymphoma Xenografts, PLoS ONE, vol.61, issue.6, p.11140, 2010.
DOI : 10.1371/journal.pone.0011140.s001
URL : https://doi.org/10.1371/journal.pone.0011140

A. Khakoo, S. Pati, and S. Anderson, Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma, The Journal of Experimental Medicine, vol.63, issue.5, pp.1235-1282, 2006.
DOI : 10.1152/ajpheart.00393.2005

A. Klopp, A. Gupta, and E. Spaeth, Concise Review: Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth?, STEM CELLS, vol.124, issue.1, pp.11-20, 2011.
DOI : 10.1002/ijc.23939

C. Gieffers, M. Kluge, and C. Merz, APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fc?? Receptors, Molecular Cancer Therapeutics, vol.12, issue.12, pp.2735-2782, 2013.
DOI : 10.1158/1535-7163.MCT-13-0323